Aclarion’s Nociscan Detects Intradiscal Biomarker, Reveals Immune-Linked Back Pain Subtype
ACON•Aclarion’s Nociscan MRS technology measured intradiscal propionic acid in Modic type 1 patients, identifying a subgroup with elevated PA and B-cell activation. These findings suggest Nociscan could differentiate mechanical, inflammatory and immune-associated back pain origins, potentially expanding its decision-support platform beyond surgical planning.
1. Study Overview
Aclarion’s Nociscan MRS platform was used to noninvasively measure propionic acid levels inside lumbar discs of patients with Modic type 1 changes. Elevated PA correlated with systemic B-cell activation, identifying an immune-linked MC1 subgroup and earning the 2026 ISSLS Best Paper Award.
2. Nociscan Technology
The MRS-based decision-support tool acquires spectral data via MRI, quantifying biochemical markers like PA to pinpoint painful discs. Originally designed to guide surgical planning, its methodology now shows potential for broader diagnostic differentiation.
3. Clinical Implications
By distinguishing mechanical, inflammatory or immune-associated pain processes, Nociscan could inform personalized treatment strategies including anti-inflammatory, antimicrobial or immune-modulating therapies. This capability addresses a major gap in standard imaging for the 266 million chronic low back pain sufferers worldwide.
4. Future Outlook
Aclarion plans to validate these findings in larger clinical studies and explore regulatory clearances for expanded indications. Success could significantly enlarge its addressable market beyond surgical decision support.
